<s id="wsj_0180.1"> 20
2 	 0 	 N/N 	 1 	 Inc. Genetics
2 	 1 	 N/N 	 1 	 Inc. Institute
2 	 6 	 NP\NP 	 1 	 Inc. Mass.
2 	 8 	 (S[dcl]\NP)/S[dcl] 	 1 	 Inc. said
6 	 4 	 (NP\NP)/(NP\NP) 	 2 	 Mass. Cambridge
9 	 10 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 it was
9 	 11 	 ((S[pss]\NP)/PP)/NP 	 1 	 it awarded <XB>
10 	 8 	 (S[dcl]\NP)/S[dcl] 	 2 	 was said
11 	 10 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 awarded was
13 	 11 	 ((S[pss]\NP)/PP)/NP 	 3 	 patents awarded
13 	 12 	 N/N 	 1 	 patents U.S.
14 	 11 	 ((S[pss]\NP)/PP)/NP 	 2 	 for awarded
15 	 14 	 PP/NP 	 1 	 Interleukin-3 for
19 	 14 	 PP/NP 	 1 	 protein for
19 	 17 	 N/N 	 1 	 protein bone
19 	 18 	 N/N 	 1 	 protein morphogenetic
<\s>
<s id="wsj_0180.2"> 21
1 	 0 	 NP[nb]/N 	 1 	 patent The
1 	 2 	 (NP\NP)/NP 	 1 	 patent for
1 	 4 	 (S[dcl]\NP)/NP 	 1 	 patent covers
3 	 2 	 (NP\NP)/NP 	 2 	 Interleukin-3 for
5 	 4 	 (S[dcl]\NP)/NP 	 2 	 materials covers
5 	 8 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 materials used <XB>
5 	 10 	 (S[b]\NP)/NP 	 1 	 materials make <XB>
7 	 4 	 (S[dcl]\NP)/NP 	 2 	 methods covers
7 	 8 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 methods used <XB>
7 	 10 	 (S[b]\NP)/NP 	 1 	 methods make <XB>
9 	 8 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to used
10 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 make to
10 	 17 	 ((S\NP)\(S\NP))/NP 	 2 	 make via
16 	 10 	 (S[b]\NP)/NP 	 2 	 factor make
16 	 11 	 NP[nb]/N 	 1 	 factor the
16 	 12 	 N/N 	 1 	 factor human
16 	 13 	 N/N 	 1 	 factor blood
16 	 14 	 N/N 	 1 	 factor cell
16 	 15 	 N/N 	 1 	 factor growth
20 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 technology via
20 	 18 	 N/N 	 1 	 technology recombinant
20 	 19 	 N/N 	 1 	 technology DNA
<\s>
<s id="wsj_0180.3"> 21
1 	 0 	 N/N 	 1 	 Ltd. Sandoz
1 	 2 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 Ltd. has
1 	 3 	 ((S[pt]\NP)/PP)/NP 	 1 	 Ltd. licensed <XB>
1 	 15 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Ltd. is <XU>
1 	 16 	 (S[ng]\NP)/NP 	 1 	 Ltd. conducting <XU>
3 	 2 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 licensed has
8 	 3 	 ((S[pt]\NP)/PP)/NP 	 3 	 rights licensed
8 	 4 	 N/N 	 1 	 rights certain
8 	 5 	 N/N 	 1 	 rights manufacturing
8 	 7 	 N/N 	 1 	 rights marketing
8 	 9 	 (NP\NP)/NP 	 1 	 rights for
10 	 9 	 (NP\NP)/NP 	 2 	 Interleukin-3 for
11 	 3 	 ((S[pt]\NP)/PP)/NP 	 2 	 from licensed
13 	 11 	 PP/NP 	 1 	 Institute from
13 	 12 	 N/N 	 1 	 Institute Genetics
16 	 15 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 conducting is
16 	 19 	 ((S\NP)\(S\NP))/NP 	 2 	 conducting with
18 	 16 	 (S[ng]\NP)/NP 	 2 	 studies conducting
18 	 17 	 N/N 	 1 	 studies preclinical
20 	 19 	 ((S\NP)\(S\NP))/NP 	 3 	 it with
<\s>
<s id="wsj_0180.4"> 24
0 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Interleukin-3 may
0 	 2 	 S[b]\NP 	 1 	 Interleukin-3 help <XB>
0 	 4 	 (S[ng]\NP)/NP 	 1 	 Interleukin-3 treating <XB>
1 	 23 	 (S[dcl]\S[dcl])\NP 	 1 	 may said
2 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 help may
2 	 3 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 2 	 help in
4 	 3 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 treating in
7 	 4 	 (S[ng]\NP)/NP 	 2 	 deficiencies treating
7 	 5 	 N/N 	 1 	 deficiencies blood
7 	 6 	 N/N 	 1 	 deficiencies cell
7 	 8 	 (S[pss]\NP)/PP 	 1 	 deficiencies associated <XB>
9 	 8 	 (S[pss]\NP)/PP 	 2 	 with associated
11 	 9 	 PP/NP 	 1 	 treatment with
11 	 10 	 N/N 	 1 	 treatment cancer
15 	 9 	 PP/NP 	 1 	 transplants with
15 	 13 	 N/N 	 1 	 transplants bone
15 	 14 	 N/N 	 1 	 transplants marrow
19 	 9 	 PP/NP 	 1 	 disorders with
19 	 17 	 N/N 	 1 	 disorders other
19 	 18 	 N/N 	 1 	 disorders blood-cell
22 	 21 	 N/N 	 1 	 Institute Genetics
22 	 23 	 (S[dcl]\S[dcl])\NP 	 2 	 Institute said
<\s>
<s id="wsj_0180.5"> 17
2 	 0 	 NP[nb]/N 	 1 	 patent The
2 	 1 	 N/N 	 1 	 patent second
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 patent describes
6 	 3 	 (S[dcl]\NP)/NP 	 2 	 protein-1 describes
6 	 4 	 N/N 	 1 	 protein-1 bone
6 	 5 	 N/N 	 1 	 protein-1 morphogenetic
9 	 3 	 (S[dcl]\NP)/NP 	 2 	 substance describes
9 	 8 	 NP[nb]/N 	 1 	 substance a
9 	 10 	 (NP\NP)/(S[dcl]\NP) 	 1 	 substance that
9 	 11 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 substance can <XB>
9 	 12 	 (S[b]\NP)/NP 	 1 	 substance induce <XB>
11 	 10 	 (NP\NP)/(S[dcl]\NP) 	 2 	 can that
12 	 11 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 induce can
13 	 12 	 (S[b]\NP)/NP 	 2 	 formation induce
13 	 14 	 (NP\NP)/NP 	 1 	 formation of
16 	 14 	 (NP\NP)/NP 	 2 	 cartilage of
16 	 15 	 N/N 	 1 	 cartilage new
<\s>
<s id="wsj_0180.6"> 21
1 	 0 	 NP[nb]/N 	 1 	 patent The
1 	 2 	 (S[dcl]\NP)/NP 	 1 	 patent covers
2 	 20 	 (S[dcl]\S[dcl])\NP 	 1 	 covers said
5 	 2 	 (S[dcl]\NP)/NP 	 2 	 proteins covers
5 	 3 	 N/N 	 1 	 proteins BMP-1
5 	 4 	 N/N 	 1 	 proteins type
8 	 2 	 (S[dcl]\NP)/NP 	 2 	 compositions covers
8 	 7 	 N/N 	 1 	 compositions pharmaceutical
8 	 11 	 (NP\NP)/(S[ng]\NP) 	 1 	 compositions for
10 	 2 	 (S[dcl]\NP)/NP 	 2 	 methods covers
10 	 7 	 N/N 	 1 	 methods pharmaceutical
10 	 11 	 (NP\NP)/(S[ng]\NP) 	 1 	 methods for
12 	 11 	 (NP\NP)/(S[ng]\NP) 	 2 	 treating for
16 	 12 	 (S[ng]\NP)/NP 	 2 	 defects treating
16 	 13 	 N/N 	 1 	 defects bone
16 	 15 	 N/N 	 1 	 defects cartilage
19 	 18 	 N/N 	 1 	 Institute Genetics
19 	 20 	 (S[dcl]\S[dcl])\NP 	 2 	 Institute said
<\s>
<s id="wsj_0180.7"> 28
1 	 0 	 NP[nb]/N 	 1 	 company The
1 	 2 	 (S[dcl]\NP)/S[em] 	 1 	 company added
3 	 2 	 (S[dcl]\NP)/S[em] 	 2 	 that added
4 	 5 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 it has
4 	 6 	 ((S[pt]\NP)/PP)/NP 	 1 	 it filed <XB>
5 	 3 	 S[em]/S[dcl] 	 1 	 has that
6 	 5 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 filed has
8 	 6 	 ((S[pt]\NP)/PP)/NP 	 3 	 applications filed
8 	 7 	 N/N 	 1 	 applications patent
9 	 6 	 ((S[pt]\NP)/PP)/NP 	 2 	 on filed
12 	 9 	 PP/NP 	 1 	 number on
12 	 10 	 NP[nb]/N 	 1 	 number a
12 	 11 	 N/N 	 1 	 number large
12 	 13 	 (NP\NP)/NP 	 1 	 number of
16 	 13 	 (NP\NP)/NP 	 2 	 proteins of
16 	 14 	 N/N 	 1 	 proteins different
16 	 15 	 N/N 	 1 	 proteins BMP
19 	 18 	 NP[nb]/N 	 1 	 patent the
19 	 20 	 (NP\NP)/NP 	 1 	 patent on
19 	 22 	 (S[dcl]\NP)/NP 	 1 	 patent is
21 	 20 	 (NP\NP)/NP 	 2 	 BMP-1 on
24 	 22 	 (S[dcl]\NP)/NP 	 2 	 first is
24 	 23 	 NP[nb]/N 	 1 	 first the
24 	 27 	 (S[pt]\NP)/NP 	 2 	 first received <XU>
25 	 26 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 it has
25 	 27 	 (S[pt]\NP)/NP 	 1 	 it received <XB>
27 	 26 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 received has
<\s>
<s id="wsj_0180.8"> 24
1 	 0 	 N/N 	 1 	 products BMP
1 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 products may
1 	 4 	 S[adj]\NP 	 1 	 products useful <XB>
1 	 10 	 (S[ng]\NP)/NP 	 1 	 products treating <XB>
2 	 23 	 (S[dcl]\S[dcl])\NP 	 1 	 may said
3 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be may
3 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 be in
3 	 9 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 2 	 be in <XU>
4 	 3 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 useful be
7 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 healing in
7 	 6 	 N/N 	 1 	 healing fracture
10 	 9 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 treating in
12 	 10 	 (S[ng]\NP)/NP 	 2 	 loss treating
12 	 11 	 N/N 	 1 	 loss bone
12 	 13 	 (S[pss]\NP)/PP 	 1 	 loss associated <XB>
14 	 13 	 (S[pss]\NP)/PP 	 2 	 with associated
16 	 14 	 PP/NP 	 1 	 disease with
16 	 15 	 N/N 	 1 	 disease periodontal
19 	 14 	 PP/NP 	 1 	 cancers with
19 	 18 	 N/N 	 1 	 cancers certain
22 	 21 	 NP[nb]/N 	 1 	 company the
22 	 23 	 (S[dcl]\S[dcl])\NP 	 2 	 company said
<\s>
